Journal article

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study.

Thomas A Rasmussen, Lakshmi Rajdev, Ajantha Rhodes, Ashanti Dantanarayana, Surekha Tennakoon, Socheata Chea, Tim Spelman, Shelly Lensing, Rachel Rutishauser, Sonia Bakkour, Michael Busch, Janet D Siliciano, Robert F Siliciano, Mark H Einstein, Dirk P Dittmer, Elizabeth Chiao, Steven Deeks, Christine Durand, Sharon R Lewin

Clin Infect Dis | Published : 2021

Abstract

BACKGROUND: Antibodies to PD-1 and CTLA-4 may perturb HIV persistence during antiretroviral therapy (ART) by reversing HIV-latency and/or boosting HIV-specific immunity leading to clearance of infected cells. We tested this hypothesis in a clinical trial of anti-PD-1 alone or in combination with anti-CTLA-4 in people living with HIV (PLWH) and cancer. METHODS: This was a substudy of the AIDS Malignancy Consortium-095 Study. ART-suppressed PLWH with advanced malignancies were assigned to nivolumab (anti-PD-1) with or without ipilimumab (anti-CTLA-4). In samples obtained pre-infusion and one and seven days after the first and fourth dose of immune checkpoint blockade (ICB), we quantified cell-..

View full abstract